Key facts
- Binx’s last known valuation is $333.9M (May 2021).
- It has raised $279.5M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Innovate UK, OrbiMed, Johnson & Johnson JJDC, EQT Life Sciences, Novartis Venture Fund — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Binx
- ·The full record, as it builds
Funding rounds
No funding rounds for Binx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Binx
Developer of a point-of-care testing platform designed to improve the well-being of communities by providing pathways to care that prioritize clinical integrity and patient convenience. The company's platform offers rapid polymerase chain reaction (PCR)-based results as well as provides a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up to increase screening and reduce infections, enabling people to get accurate diagnostic reports through discreet testing.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2005
- Employees
- 91
- Website
- mybinxhealth.com/
- Ownership
- Privately Held (backing)
Binx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Binx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Binx in its N-PORT filings yet. We sweep new filings monthly.